Constant, sustained drug delivery for obesity, T2D, & metabolic syndrome (NMD)
Our novel nanochannel membrane device (NMD) allows for sustained, low-dose and constant administration of the thyroid receptor-β (TRβ)-selective agonist GC-1 (sobetirome). Steady GC-1 administration from the NMD, consisting of an implantable nanochannel membrane, as an alternative to conventional daily administration, which is subject to compliance issues in clinical settings. We have published on this project in a DIO mouse model (Int. J. Obes.), healthy rats (Nanomedicine Nanotechnol. Biol. Med.), and in a spontaneously obese non-human primate (Biomed. Microdevices). Sustained low-dose delivery of GC-1 from our minimally invasive subcutaneous implant provides a valuable approach to induce weight loss and manage obesity and comorbidities, including type 2 diabetes.